Predictors of lung function test severity and outcome in systemic sclerosis-associated interstitial lung disease

PLoS One. 2017 Aug 1;12(8):e0181692. doi: 10.1371/journal.pone.0181692. eCollection 2017.

Abstract

Systemic sclerosis-related interstitial lung disease (SSc-ILD) is the leading cause of death in SSc. In this study, we aimed to describe the baseline severity and evolution of forced vital capacity (FVC) and diffusing capacity for carbon monoxide (DLCO) in patients with SSc-ILD and to assess the baseline clinical, biological and high-resolution CT scan (HRCT) predictors of this evolution. Baseline and serial FVC and DLCO were collected in 75 SSc-ILD patients followed during 6.4±4.2 years (n = 557 individual data). FVC and DLCO evolution was modelled using a linear mixed model with random effect. During follow-up, FVC was stable while DLCO significantly decreased (-1.5±0.3%/year (p<0.0001). Baseline NYHA functional class III/IV, extensive SSc-ILD on HRCT and DLCO<80% were associated with a lower baseline FVC. Absence of digital ulcers extensive SSc-ILD, and FVC<80% and were associated with a lower baseline DLCO. Presence or history of digital ulcers and presence of pulmonary hypertension at baseline or during follow-up were associated with a faster decline of DLCO overtime. Neither age, gender, subtype of SSc nor specificity of autoantibodies were associated with baseline severity or outcome of lung function tests. In this SSc-ILD population, FVC was therefore stable while DLCO significantly declined over time. ILD extension was associated with baseline FVC and DLCO but not with their evolution. Presence or history of digital ulcers and pulmonary hypertension were predictors of a faster decline of DLCO over time.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Carbon Monoxide / chemistry
  • Cyclophosphamide / therapeutic use
  • Diffusion
  • Echocardiography
  • Female
  • Fingers / pathology
  • Follow-Up Studies
  • Humans
  • Hypertension, Pulmonary / physiopathology
  • Linear Models
  • Lung / physiopathology
  • Lung Diseases, Interstitial / complications*
  • Lung Diseases, Interstitial / physiopathology
  • Male
  • Methotrexate / therapeutic use
  • Middle Aged
  • Mycophenolic Acid / therapeutic use
  • Pulmonary Diffusing Capacity*
  • Respiratory Function Tests*
  • Scleroderma, Systemic / complications*
  • Scleroderma, Systemic / physiopathology
  • Ulcer / pathology
  • Young Adult

Substances

  • Carbon Monoxide
  • Cyclophosphamide
  • Mycophenolic Acid
  • Methotrexate

Grants and funding

The authors received no specific funding for this work.